Program Official

Principal Investigator

Samuel J
Milanovich
Awardee Organization

Sanford Research/Usd
United States

Fiscal Year
2024
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Sanford Community Cancer Program of the North Central Plains (NCORP)

The Sanford Community Cancer Program (SCCP) remains committed to its original goals and aims as stated in our 2013 application. The SCCP continues to increase patient participation in cancer control, prevention, care delivery, treatment, and imaging studies across its expanding network. The rural communities of the upper Midwest and Central Plains represent a large underserved population for cancer treatment, care delivery and clinical trials (PMID:24097196 PMID:22046848 PMID:19621978). The reasons for this disparity are multifactorial but a main obstacle is access to services in rural regional areas. Sanford Health has developed a network of hospitals, cancer centers and clinics to provide high-quality, multi-disciplinary cancer treatment, clinical trials, and cancer care delivery to this underserved area. Sanford Health has designated cancer care as a Center of Excellence; elevating cancer care as a top priority to the patients it serves. The SCCP has expanded from five to seven components in the past five years, adding two new components to improve trial access in rural and underserved areas. It is hypothesized that this disparity in care for this rural population can be improved by utilizing the organized SCCP network community. This proposal describes how the NCI Community Oncology Research Program (NCORP) partnership will help deliver clinical care and offer clinical trials across the rural area served by the SCCP. This will be accomplished through the following aims: 1. Maintain and enhance robust accrual to NCI Division of Cancer Prevention (DCP) supported clinical trials through seven components. 2. Address disparities in clinical trial accrual in underserved and underrepresented populations to increase participation. 3. Cultivate innovative access points to address barriers to clinical trial accrual through outreach and telemedicine. 4. Expand Cancer Care Delivery Research infrastructure. Through these four aims the Sanford Community Cancer Program will continue to offer NCI clinical trials and provide state-of-the-art cancer treatment and cancer care delivery to millions of people across six states in rural America. The SCCP's ability to provide clinical trials through outreach and telemedicine to this underserved rural population of patients increases their opportunity for participation in a trial as a treatment option. Telemedicine services are currently provided in existing Sanford Clinics in rural communities to deliver oncology consultations, surveillance exams and chemotherapy oversight. As a community based health care organization, the SCCP will participate in the development and implementation of cancer care delivery research to better understand and improve patient outcomes. The SCCP will design and develop additional community based investigator-initiated Cancer Care Delivery pilot projects with the goal to collaborate with the SCCP's primary Research Bases.
  • Parikh K, Mandrekar SJ, Allen-Ziegler K, Esplin B, Tan AD, Marchello B, Adjei AA, Molina JR. A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance). The oncologist. 2020 Jun;25(6):523-531. Epub 2019 Dec 24. PMID: 31872928
  • Quick AM, Dockter T, Le-Rademacher J, Salani R, Hudson C, Hundley A, Terstriep S, Streicher L, Faubion S, Loprinzi CL, Coleman JS, Wang KC, Lustberg M. Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors. Maturitas. 2021 Feb;144:37-44. Epub 2020 Dec 2. PMID: 33358206
  • Barton DL, Atherton PJ, Satele DV, Qin R, Dakhil S, Pipe T, Hobday T, Fee-Schroeder K, Loprinzi CL. A randomized phase II trial evaluating two non-pharmacologic interventions in cancer survivors for the treatment of sleep-wake disturbances: NCCTG N07C4 (Alliance). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2020 Dec;28(12):6085-6094. Epub 2020 Apr 19. PMID: 32307658
  • Halfdanarson TR, Foster NR, Kim GP, Haddock MG, Dakhil SR, Behrens RJ, Alberts SR. N064A (Alliance): Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Adenocarcinoma. The oncologist. 2022 Jul 5;27(7):534-e546. PMID: 35285484
  • Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. The New England journal of medicine. 2016 Jul 14;375(2):134-42. PMID: 27410922
  • Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR Jr, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA. 2017 Jan 3;317(1):48-58. PMID: 28030702
  • Halfdanarson TR, Foster NR, Kim GP, Meyers JP, Smyrk TC, McCullough AE, Ames MM, Jaffe JP, Alberts SR. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance). The oncologist. 2019 May;24(5):589-e160. Epub 2019 Jan 24. PMID: 30679315
  • Galanis E, Anderson SK, Twohy EL, Carrero XW, Dixon JG, Tran DD, Jeyapalan SA, Anderson DM, Kaufmann TJ, Feathers RW, Giannini C, Buckner JC, Anastasiadis PZ, Schiff D. A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. Cancer. 2019 Nov 1;125(21):3790-3800. Epub 2019 Jul 10. PMID: 31290996
  • Jaeckle KA, Anderson SK, Twohy EL, Dixon JG, Giannini C, Jenkins R, Egorin MJ, Sarkaria JN, Brown PD, Flynn PJ, Schwerkoske J, Buckner JC, Galanis E. Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). Journal of neuro-oncology. 2019 Jul;143(3):573-581. Epub 2019 May 22. PMID: 31119479
  • Park H, Qin R, Smith TJ, Atherton PJ, Barton DL, Sturtz K, Dakhil SR, Anderson DM, Flynn K, Puttabasavaiah S, Le-Lindqwister NA, Padula GD, Loprinzi CL. North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause (New York, N.Y.). 2015 Jun;22(6):627-32. PMID: 25423327
  • Yoon HH, Ou FS, Soori GS, Shi Q, Wigle DA, Sticca RP, Miller RC, Leenstra JL, Peller PJ, Ginos B, Heying E, Wu TT, Drevyanko TF, Ko S, Mattar BI, Nikcevich DA, Behrens RJ, Khalil MF, Kim GP, Alberts SR. Induction versus no induction chemotherapy before neoadjuvant chemoradiotherapy and surgery in oesophageal adenocarcinoma: a multicentre randomised phase II trial (NCCTG N0849 [Alliance]). European journal of cancer (Oxford, England : 1990). 2021 Jun;150:214-223. Epub 2021 Apr 29. PMID: 33934058
  • Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, Dispenzieri A, Kahanic SP, Thakuri MC, Reu FJ, Reynolds CM, Orlowski RZ, Barlogie B. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood cancer journal. 2020 May 11;10(5):53. PMID: 32393732
  • McWilliams RR, Foster NR, Mahoney MR, Smyrk TC, Murray JA, Ames MM, Horvath LE, Schneider DJ, Hobday TJ, Jatoi A, Meyers JP, Goetz MP. North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer. 2017 Sep 15;123(18):3494-3501. Epub 2017 May 10. PMID: 28493308
  • Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet (London, England). 2017 Feb 4;389(10068):519-527. Epub 2016 Dec 23. PMID: 28017406
  • Bhatia AK, Lee JW, Pinto HA, Jacobs CD, Limburg PJ, Rubin P, Arusell RM, Dunphy EP, Khandekar JD, Reiner SA, Baez-Diaz L, Celano P, Li S, Li Y, Burtness BA, Adams GL, Pandya KJ. Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer. 2017 Dec 1;123(23):4653-4662. Epub 2017 Aug 7. PMID: 28786105